OBT at a glance
Pioneering an Innovative Approach for the Development of First-in-Class Cancer Therapies
Oxford BioTherapeutics is a clinical-stage oncology company, developing first-in-class antibody-based therapies to improve patient outcomes. Our proprietary, proteomic target discovery platform, OGAP®-Verify, specialises in identifying novel membrane-based protein targets.
This platform supports the development of antibody-drug conjugates (ADCs), chimeric antigen receptors (CAR-Ts), immuno-oncology antibodies (IOs), radiopharmaceutical and bispecific therapeutic modalities.
We continuously enhance our OGAP®-Verify database to accurately represent patient tumours and the tumour microenvironment. Our fully integrated discovery and development capabilities span from target identification to IND-enabling studies.
View our Pipeline
OBT’s mission is to become a key player in the ADC and T-cell engagers (TCE) field, with a reputation for innovation, scientific excellence, and commitment to improving patient outcomes and bringing much-needed therapies to patients worldwide
Our Team
Our success at Oxford BioTherapeutics is driven by a team that expertly combines scientific rigour with medical expertise
Christian Rohlff, PhD
Chief Executive Officer, Oxford
Christian has been CEO of Oxford BioTherapeutics since founding the company and acquiring key technology, bioinformatics data and intellectual property. He brings more than 20 years of experience in the international biotechnology industry. Following his PhD in Pharmacology from Georgetown University, Christian worked at the US National Cancer Institute in Bethesda, Maryland. Prior to founding OBT, he held a number of positions of increasing seniority with Oxford Glycosciences, and led the company’s partnerships in oncology with Pfizer, GSK, Bayer, Wyeth, Takeda, Oxford University and the FDA.
Investors
Oxford BioTherapeutics is Supported by a Syndicate of Leading Specialist Investors
A major portion of the investment into our ADC, IO, CAR-T and bispecific pipeline comes from strategic alliances with leading companies in the oncology field.
